Evaluation of a Plasma Protein Profile as a Predictive Biomarker for Metastatic Relapse in Triple Negative Breast Cancer Patients

Launched by CENTRE JEAN PERRIN · Jun 17, 2020

Keywords

ClinConnect Summary

The INSTIGO study is a clinical trial designed to investigate whether certain proteins in the blood can help predict the chances of cancer coming back in women with triple negative breast cancer. This type of breast cancer can be more challenging to treat, so understanding how to identify those at higher risk of metastatic relapse—when cancer spreads to other parts of the body—could be very important for patient care. The study will also look into other potential indicators, like specific immune cells and genetic material in the blood, to see if they can provide additional insights.

To participate in this study, women must be over 18 years old and have been diagnosed with non-metastatic, triple negative breast cancer. They should also be able to understand French and be able to provide written consent to join the trial. Participants can expect to provide blood samples at various stages of their follow-up appointments, and their results may contribute to important research that could improve future cancer treatments. This study is currently recruiting participants, which means it's actively looking for women who meet the criteria and are willing to take part.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Female
• • Age \> 18 years
• • Diagnosed with primitive, non-metastatic, histologically proved, triple negative breast cancer
• • Patient able to understand the French language
• • Patient affiliated to social security
• • Obtaining signed written consent
• Exclusion Criteria:
• • Persons deprived of their freedom or under guardianship or incapable of giving consent
• • Refusal to participate